Polarity of long-term synaptic gain change is related to postsynaptic spike firing at a cerebellar inhibitory synapse
Interventions: CagriSema (Cagrilintide B and Semaglutide I), placebo Primary Outcome Measure: Relative change in body weight Time Frame: From baseline (week 0) to week 80 Study Details Source VK2735 for Weight Management Phase 3 (VANQUISH 1) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes
Standard doses: Low dose: 250mcg (0.25mg) Standard dose: 350-400mcg (0.35-0.4mg) High dose: 500mcg (0.5mg) A 5mg vial contains: 20 doses at 250mcg 14 doses at 350mcg 10 doses at 500mcg Why 5mg is the standard size Practical dosing : Matches typical 2-4 week cycles with twice-daily dosing
Aliquot to avoid repeated freeze-thaw cycles
Continuous real-time monitoring of inflammatory markers through AI-integrated platforms enables dynamic treatment adjustments
